Marinus Pharmaceuticals | MRNS - Des Atouts



Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
ALKERMES USD 4.26B 1.77B 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
Eisai JPY 1.45T 37.11B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Incyte USD 7.34B 381.14M 2026-03
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Supernus Pharmaceuticals USD 1.5B 48.08M 2026-03
UCB EUR 18.16B 971M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03